Giant cell arteritis (GCA) is the most frequent type of vasculitis, occurring in people older than 50 years. So far, treatment has been limited to corticosteroids and methotrexate only. Areas covered: Interleukin-6 (IL-6) plays a role in the pathophysiology of GCA. This review covers recent advances in the treatment of GCA with tocilizumab (TCZ), which specifically binds to both soluble and membrane-bound IL-6R and inhibits IL-6R-mediated signaling. Expert commentary: Two randomized controlled trials recently showed the efficacy of the IL-6 receptors inhibitor monoclonal antibody TCZ for the induction and maintenance of remission in patients with new-onset and relapsing GCA. Furthermore, addition of TCZ to prednisone led to a reduction in the cumulative prednisone doses required to control GCA. The profile of adverse events was balanced across treatment groups and no safety concerns were raised during the trial.

Tocilizumab for the treatment of giant cell arteritis / Schirmer, Michael; Muratore, Francesco; Salvarani, Carlo. - In: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. - ISSN 1744-8409. - 14:5(2018), pp. 339-349.

Tocilizumab for the treatment of giant cell arteritis

Muratore, Francesco;Salvarani, Carlo
2018

Abstract

Giant cell arteritis (GCA) is the most frequent type of vasculitis, occurring in people older than 50 years. So far, treatment has been limited to corticosteroids and methotrexate only. Areas covered: Interleukin-6 (IL-6) plays a role in the pathophysiology of GCA. This review covers recent advances in the treatment of GCA with tocilizumab (TCZ), which specifically binds to both soluble and membrane-bound IL-6R and inhibits IL-6R-mediated signaling. Expert commentary: Two randomized controlled trials recently showed the efficacy of the IL-6 receptors inhibitor monoclonal antibody TCZ for the induction and maintenance of remission in patients with new-onset and relapsing GCA. Furthermore, addition of TCZ to prednisone led to a reduction in the cumulative prednisone doses required to control GCA. The profile of adverse events was balanced across treatment groups and no safety concerns were raised during the trial.
9-mag-2018
14
5
339
349
Tocilizumab for the treatment of giant cell arteritis / Schirmer, Michael; Muratore, Francesco; Salvarani, Carlo. - In: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. - ISSN 1744-8409. - 14:5(2018), pp. 339-349.
Schirmer, Michael; Muratore, Francesco; Salvarani, Carlo
File in questo prodotto:
File Dimensione Formato  
schirmer2018.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 943.68 kB
Formato Adobe PDF
943.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1167268
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
social impact